Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of ZR-02-01 Matrix Fentanyl Patch in Chronic Pain
NCT00126763Phase 3Terminated
- Sponsor
- ZARS Pharmaceuticals
- Start
- Jul 2005
- Primary completion
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fentanyl (transdermal patch + oral transmucosal lozenge) in chronic pain, sponsored by ZARS Pharmaceuticals. Primary endpoint: Number of participants with adverse events at 12 months. Started Jul 2005; status: terminated.
02
Drugs
fentanyl (transdermal patch + oral transmucosal lozenge)
03
Conditions
chronic pain
Beyond the preview
Go deeper on NCT00126763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00126763.